Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2.
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-TPM3, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Tropomyosin 3 also known as TPM3 is an actin-binding protein that stabilizes actin filaments. This protein plays an important role in maintaining cytoskeleton integrity and regulating cell contraction. Tropomyosin 3 has a molecular weight of approximately 32.5 kDa and is widely expressed in various tissues especially in muscle cells and in some non-muscle tissues. This protein interacts with other proteins to form complexes that modulate the dynamics of the actin filament systems.
Biological function summary
Tropomyosin 3 modulates the access of other actin-binding proteins to the actin filament by covering and uncovering binding sites. It partners with actin and troponin complexes influencing muscle contraction and cell motility. Additionally TPM3 regulates the stability and flexibility of actin cortex important for cell shape and movement. In non-muscle cells it supports the formation of cell structures needed for signaling and transportation.
Pathways
Tropomyosin 3 functions in the regulation of the actin cytoskeleton pathway and the muscle contraction pathway. It coordinates with proteins like actin and myosin to facilitate these processes. In the actin cytoskeleton pathway TPM3 balances polymerization and depolymerization of actin important for maintaining cellular structures. The muscle contraction pathway relies on TPM3 to regulate calcium binding supporting muscular function and responsiveness.
Tropomyosin 3 mutations link to conditions like congenital myopathy and nemaline myopathy. Mutations in TPM3 affect muscle fiber regulation leading to muscle weakness and structural abnormalities. Congenital myopathy involves other proteins such as nebulin which cooperate with TPM3 in maintaining muscle architecture. In nemaline myopathy improper expression or structure of TPM3 contributes to defective sarcomere formation impairing muscle function.
